These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10866299)

  • 1. Vaccine-induced apoptosis: a novel clinical trial end point?
    Amin S; Robins RA; Maxwell-Armstrong CA; Scholefield JH; Durrant LG
    Cancer Res; 2000 Jun; 60(12):3132-6. PubMed ID: 10866299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.
    Ullenhag GJ; Spendlove I; Watson NF; Indar AA; Dube M; Robins RA; Maxwell-Armstrong C; Scholefield JH; Durrant LG
    Clin Cancer Res; 2006 Dec; 12(24):7389-96. PubMed ID: 17121873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind randomized-phase II trial comparing immunization with antiidiotype goat antibody vaccine SCV 106 versus unspecific goat antibodies in patients with metastatic colorectal cancer.
    Samonigg H; Wilders-Truschnig M; Kuss I; Plot R; Stöger H; Schmid M; Bauernhofer T; Tiran A; Pieber T; Havelec L; Loibner H
    J Immunother; 1999 Nov; 22(6):481-8. PubMed ID: 10570746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses.
    Buckley DT; Robins AR; Durrant LG
    Hum Antibodies Hybridomas; 1995; 6(2):68-72. PubMed ID: 7492753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current concepts in immunotherapy for the treatment of colorectal cancer.
    Indar A; Maxwell-Armstrong CA; Durrant LG; Carmichael J; Scholefield JH
    J R Coll Surg Edinb; 2002 Apr; 47(2):458-74. PubMed ID: 12018689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody.
    Robins RA; Denton GW; Hardcastle JD; Austin EB; Baldwin RW; Durrant LG
    Cancer Res; 1991 Oct; 51(19):5425-9. PubMed ID: 1913661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer.
    Maxwell-Armstrong CA; Durrant LG; Buckley TJ; Scholefield JH; Robins RA; Fielding K; Monson JR; Guillou P; Calvert H; Carmichael J; Hardcastle JD
    Br J Cancer; 2001 Jun; 84(11):1443-6. PubMed ID: 11384090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55.
    Durrant LG; Maxwell-Armstrong C; Buckley D; Amin S; Robins RA; Carmichael J; Scholefield JH
    Clin Cancer Res; 2000 Feb; 6(2):422-30. PubMed ID: 10690519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
    Posner MC; Niedzwiecki D; Venook AP; Hollis DR; Kindler HL; Martin EW; Schilsky RL; Goldberg RM; Mayer RJ
    Ann Surg Oncol; 2008 Jan; 15(1):158-64. PubMed ID: 18008108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for recurrent colorectal cancers with human monoclonal antibody SK-1.
    Koda K; Glassy MC; McKnight ME; Yasutomi J; Saito N; Dan M; Nakajima N
    Anticancer Res; 2001; 21(1B):621-7. PubMed ID: 11299816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-idiotype vaccines for immunotherapy.
    Bhattacharya-Chatterjee M; Chatterjee SK; Foon KA
    Curr Opin Mol Ther; 2001 Feb; 3(1):63-9. PubMed ID: 11249733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.
    Scartozzi M; Bearzi I; Berardi R; Mandolesi A; Fabris G; Cascinu S
    J Clin Oncol; 2004 Dec; 22(23):4772-8. PubMed ID: 15570078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technology evaluation: Onyvax-105, Onyvax.
    Blumenthal RD
    Curr Opin Mol Ther; 2003 Dec; 5(6):668-72. PubMed ID: 14755894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colorectal cancer as a model for immunotherapy.
    Foon KA; Yannelli J; Bhattacharya-Chatterjee M
    Clin Cancer Res; 1999 Feb; 5(2):225-36. PubMed ID: 10037169
    [No Abstract]   [Full Text] [Related]  

  • 15. Developing effective cancer vaccines: design and monitoring are critical.
    Armstrong A; Dermime S
    Br J Cancer; 2001 Jun; 84(11):1433-6. PubMed ID: 11384088
    [No Abstract]   [Full Text] [Related]  

  • 16. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival.
    Moulton HM; Yoshihara PH; Mason DH; Iversen PL; Triozzi PL
    Clin Cancer Res; 2002 Jul; 8(7):2044-51. PubMed ID: 12114402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis.
    Durrant LG; Harding SJ; Green NH; Buckberry LD; Parsons T
    Cancer Res; 2006 Jun; 66(11):5901-9. PubMed ID: 16740730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous detection of apoptosis and proliferation in colorectal carcinoma by multiparameter flow cytometry allows separation of high and low-turnover tumors with distinct clinical outcome.
    Rupa JD; de Bruïne AP; Gerbers AJ; Leers MP; Nap M; Kessels AG; Schutte B; Arends JW
    Cancer; 2003 May; 97(10):2404-11. PubMed ID: 12733138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.
    Conry RM; Curiel DT; Strong TV; Moore SE; Allen KO; Barlow DL; Shaw DR; LoBuglio AF
    Clin Cancer Res; 2002 Sep; 8(9):2782-7. PubMed ID: 12231517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization against tumor cell surface complement-regulatory proteins.
    Durrant LG; Spendlove I
    Curr Opin Investig Drugs; 2001 Jul; 2(7):959-66. PubMed ID: 11757799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.